Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03972046
Title Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors David Lee

skin melanoma



Dabrafenib + Talimogene laherparepvec + Trametinib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
TriHealth Cancer Institute - Kenwood Cincinnati Ohio 45236 United States Details
*Shaded cells indicate that there was no data available from for the field